Solid organ transplant recipients are at 3-10 times higher risk of cancer compared to non-transplant patients, due to long-standing immunosuppression. Cellular therapies, such as CAR-T or virus-specific T cell therapies, have emerged as novel therapies for cancers and infectious diseases, but their use in transplant patients is challenging because of safety and efficacy concerns.
As there has been a growing data on cellular therapies in transplant population, the goals of our conference are to learn up-to-date cellular therapies treatment options for transplant patients, and to learn patients’ perspectives from those living with cancer post-transplants.
- Understand the cancer burden in transplant recipients
- Learn up-to-date cellular therapies for transplant patients
- Learn patients’ perspectives from those living with cancer post-transplant
This course is targeted to transplant clinicians (nephrologists, surgeons, advanced practitioners, nurses, social workers), oncologists, as well as transplant recipients and their care partners.